Skip to content

Prospective, multicenter, randomized, paired, blind, non-inferior clinical trial evaluating the efficacy and safety of Nd:YAG picosecond laser therapy apparatus for the treatment of freckles

Prospective, multicenter, randomized, paired, blind, non-inferior clinical trial evaluating the efficacy and safety of Nd:YAG picosecond laser therapy apparatus for the treatment of freckles

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082063
Enrollment
Unknown
Registered
2024-03-20
Start date
2023-05-22
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

freckles

Interventions

cantrol group :532nm Nd:YAG picosecond laser

Sponsors

Hospital of Dermatology, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-65 years old, gender unlimited; (2) Diagnosis of facial freckles and visual bilateral relative symmetry; (3) Fitzpatrick skin type ?-V; (4) Voluntarily participate in the experiment and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with a history of photosensitive epilepsy. (2) Patients with a history of squamous cell carcinoma or melanoma. (3) Patients with a history of healing disorders or keloids. (4) Patients with known systemic infection or local infection at the site to be treated in the trial. (5) Patients with a history of immunosuppression/immune disorders (including HIV infection or AIDS) or those taking immunosuppressive drugs. (6) Patients with a history of sunburn in the past 1 month. (7) Surgical treatments received in the proposed treatment area within the past 1 month included: minimally invasive, plastic surgery, ultraviolet phototherapy, intense pulsed light, laser, and radiofrequency therapy. (8) Patients who have taken or are taking anticoagulant drugs or drugs that affect wound healing in the past 1 month. (9) Patients who have taken or are taking medications known to increase light sensitivity in the past 1 month. (10) Patients who currently suffer from epilepsy, emotional disorders or cognitive disorders and cannot cooperate with treatment. (11) Pregnant or lactating women or those who were pregnant or planned to have a baby during the trial. (12) Participants who have participated in other intervention clinical trials within 1 month. (13) Other conditions deemed unsuitable for participation in this clinical trial by the investigator.

Design outcomes

Primary

MeasureTime frame
Lesion clearance rate;

Secondary

MeasureTime frame
Therapeutic effect;GAIS;Subject Satisfaction;

Countries

China

Contacts

Public ContactTong Lin

Hospital of Dermatology, Chinese Academy of Medical Sciences

ddlin@hotmail.com+86 139 5190 2258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026